Nature Medicine, Published online: 07 March 2025; doi:10.1038/s41591-025-03579-w
An updated analysis of the DYNAMIC biomarker-driven trial, including mature survival data at 5 years, supports a ctDNA-guided approach to adjuvant chemotherapy for stage II colon cancer.
